HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, has announced its plans to voluntarily delist from the Nasdaq Capital Market and deregister its common stock under the Securities Exchange Act of 1934. This decision comes in light of the impending Asset Sale to Gilead Sciences, Inc., which involves the transfer of assets related to HOOKIPA's HB-400 and HB-500 programs. Following the Asset Sale, HOOKIPA intends to dissolve and liquidate, subject to stockholder approval at a special meeting scheduled for July 29, 2025. The company cites the economic burden of ongoing reporting requirements as a factor in its decision, as compliance would diminish the assets available for distribution to stockholders. If approved, HOOKIPA plans to file a Certificate of Dissolution with the Delaware Secretary of State, marking the commencement of its winding up and liquidation process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.